SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-034208
Filing Date
2023-03-20
Accepted
2023-03-20 07:06:15
Documents
14
Period of Report
2023-03-20
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm239961d1_8k.htm   iXBRL 8-K 24064
2 EXHIBIT 99.1 tm239961d1_ex99-1.htm EX-99.1 233624
6 GRAPHIC tm239961d1_ex99-1img01.jpg GRAPHIC 12617
  Complete submission text file 0001104659-23-034208.txt   467780

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvlp-20230320.xsd EX-101.SCH 3033
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvlp-20230320_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvlp-20230320_pre.xml EX-101.PRE 22595
8 EXTRACTED XBRL INSTANCE DOCUMENT tm239961d1_8k_htm.xml XML 3598
Mailing Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807
Business Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807 9088091300
RVL Pharmaceuticals plc (Filer) CIK: 0001739426 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38709 | Film No.: 23744927
SIC: 2834 Pharmaceutical Preparations